Retatrutide

Triple-Hormone Receptor Agonist for Advanced Metabolic Research

Retatrutide (development code LY3437943) represents a next-generation research peptide in the field of metabolic science. As a single-molecule triple agonist engineered to simultaneously activate the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors, it offers researchers a unique tool to study the complex interplay and potential synergistic effects of three key metabolic hormone pathways. This innovative approach to poly-pharmacology allows for investigation into mechanisms that may enhance weight reduction, improve glycemic control, and increase energy expenditure beyond single or dual agonists. Supplied as a lyophilized powder for research purposes only, Retatrutide is intended for controlled, non-human laboratory studies aimed at elucidating the frontiers of metabolic regulation and receptor signaling cascades.

Complete Research Kit Contents & Verification

Each research order provides a complete experimental package designed for cutting-edge laboratory investigation:

• Primary Research Compound: 10 sterile glass vials containing lyophilized Retatrutide peptide powder (specify dose per vial, e.g., 2mg or 5mg).

• Reconstitution Solution: 30ml vial of sterile Bacteriostatic Water (0.9% Benzyl Alcohol), essential for creating stable peptide solutions for experimental use.

• Laboratory Administration Tools: Pack of sterile 1ml insulin syringes (29G x 1/2″) for precise measurement and transfer in accordance with advanced research protocols.

• Sterilization Supplies: Individually wrapped alcohol prep swabs to maintain aseptic technique during vial handling and reconstitution.

• Research Protocol Documentation:

  • Dosing Schedule: Standardized administration protocol based on emerging preclinical data, tailored for research models in metabolic syndrome, obesity, and diabetes.

  • Usage Instructions: Comprehensive guide covering reconstitution math, storage conditions (-20°C to -80°C recommended for maximum stability), handling safety, and experimental design considerations for this novel compound.

• Quality Verification: Certificate of Analysis (CoA) provided with each batch, detailing:

  • Purity Analysis (>97% by UPLC/HPLC)

  • Amino Acid Sequence Verification (Mass Spectrometry)

  • Correct Folding & Disulfide Bond Formation (Circular Dichroism optional)

  • Sterility Testing Results

  • Endotoxin Levels (<10 EU/mg)

  • Residual Solvent Analysis

  • Net Peptide Content

  • Peptide Mapping for Identity Confirmation

Research Applications & Scientific Utility

In a laboratory setting, Retatrutide enables pioneering investigation into the combined activation of three major metabolic receptors. Primary research applications include studying the synergistic effects on weight reduction and energy expenditure, investigating enhanced glycemic control through multiple pathways, researching the balance between GIP’s anabolic effects and glucagon’s catabolic effects, exploring the mitigation of side effects through receptor activity profiling, and modeling the potential for treatment of complex metabolic diseases beyond type 2 diabetes and obesity. As a research tool, it allows scientists to probe questions about optimal receptor activation ratios, tissue-specific effects, and the downstream integration of signals from the GIP, GLP-1, and glucagon pathways in controlled experimental models.

Laboratory Handling & Safety Protocol

• Storage: Store unopened lyophilized peptide vials at -20°C or preferably -80°C for long-term stability of this complex molecule. Reconstituted solutions should be aliquoted and stored at -20°C to -80°C and used promptly to ensure experimental integrity.

• Reconstitution: Must be performed under sterile laboratory conditions using the provided bacteriostatic water, following the specific guidelines to ensure proper solubility and stability of the triple-agonist structure.

• Laboratory Safety: Standard personal protective equipment (PPE) including lab coat, nitrile gloves, and safety glasses must be worn. Follow institutional biosafety level (BSL) guidelines for handling novel biochemical reagents. Treat as a potent research compound with unknown full activity profile.

• Documentation: The provided CoA is essential for research integrity. Detailed record-keeping of lot numbers and storage conditions is crucial for reproducibility given the novelty of this research compound.

⚠️ Critical Compliance & Intended Use Disclaimer:

THIS PRODUCT IS SOLD FOR RESEARCH USE ONLY (RUO). NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

1. Intended Use: Retatrutide is supplied as a novel biochemical reagent for laboratory research purposes only. It is intended for use by qualified researchers in controlled settings studying advanced metabolic pharmacology. The included “dosing schedule” refers to experimental research model protocols only.

2. Not for Human Consumption: Under no circumstances is this product intended for administration to humans or animals. It is an investigational research compound, not a drug, supplement, or therapeutic. Its safety profile in humans is not established. The provided supplies are for laboratory use only.

3. Regulatory Status: This product is an investigational compound that has not been approved for any use by the FDA or any global health authority. It is supplied solely to facilitate basic and translational research.

4. Intellectual Property Notice: Retatrutide (LY3437943) is an investigational compound of Eli Lilly and Company. This supply is for non-commercial research use only in accordance with applicable research use exemptions.

5. Researcher Responsibility: It is the sole responsibility of the purchasing individual/institution to ensure compliance with all regulations and to use this compound strictly for legitimate, non-human research within approved ethical guidelines.